Company InfoNewsInvestor InformationResearchDevelopmentCareersBusiness DevelopmentResourcesDrugs databaseBack to the home pageSearch  
Drugs database
Drugs A-Z

Brands A-Z

Drugs by categories

Drugs by manufacturer

Drugs by packager

Antibiotics for sale

Online Viagra bestellen in Nederland

Home / Drugs / Starting with A / Alefacept 		 
Alefacept
  

Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD.
BrandsAmevive
CategoriesImmunomodulatory Agents
Immunosuppressive Agents
PackagersAstellas Pharma Inc.
Ben Venue Laboratories Inc.
Pierre Fabre
SynonymsASP0485

indication

As an immunosuppressive drug, Alefacept can be used for treatment of moderate to severe chronic plaque psoriasis

pharmacology

Interferes with lymphocyte activation by specifically binding to the lymphocyte antigen, CD2, and inhibiting LFA-3/CD2 interaction. Activation of T lymphocytes involving the interaction between LFA-3 on antigen-presenting cells and CD2 on T lymphocytes plays a role in the pathophysiology of chronic plaque psoriasis. Also causes a reduction in subsets of CD2+ T lymphocytes as well as CD4+ and CD8+ T lymphocytes.

mechanism of action

Inhibits T-lymphocyte activation and production by binding to the CD2 lymphocyte antigen.

half life

~270 hours

Terms of Use